Merck Sees 2022 Sales Up Nearly 20%, Mostly On New COVID Pill
(Fixes day of the week in first paragraph) By Michael Erman (Reuters) -Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir. The drugmaker said sales of the COVID-19 drug were $952 million in the…
